Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
10 studies found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Genital Diseases, Female"
Show Display Options
Rank Status Study
1 Recruiting Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer
Condition: Ovarian Epithelial Cancer
Intervention: Drug: SPL-108
2 Recruiting Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Conditions: Prostate Cancer;   Sexual Dysfunction and Infertility;   Sexuality
Interventions: Other: communication intervention;   Other: counseling intervention;   Other: nutrition intervention;   Other: questionnaire administration
3 Recruiting Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
Conditions: Malignant Female Reproductive System Neoplasm;   Malignant Hepatobiliary Neoplasm;   Partner;   Stage III Breast Cancer;   Stage III Cervical Cancer;   Stage III Colorectal Cancer;   Stage III Lung Cancer;   Stage III Prostate Cancer;   Stage III Skin Melanoma;   Stage III Uterine Corpus Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Colorectal Cancer;   Stage IIIA Lung Carcinoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Colorectal Cancer;   Stage IIIB Lung Carcinoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colorectal Cancer;   Stage IIIC Skin Melanoma;   Stage IIIC Uterine Corpus Cancer;   Stage IV Breast Cancer;   Stage IV Cervical Cancer;   Stage IV Colorectal Cancer;   Stage IV Lung Cancer;   Stage IV Prostate Cancer;   Stage IV Skin Melanoma;   Stage IV Uterine Corpus Cancer;   Stage IVA Cervical Cancer;   Stage IVA Colorectal Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Cervical Cancer;   Stage IVB Colorectal Cancer;   Stage IVB Uterine Corpus Cancer
Interventions: Behavioral: Cognitive Behavior Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Survey Administration
4 Recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Clear Cell Adenocarcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Mucinous Adenocarcinoma;   Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinofibroma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
5 Recruiting Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
6 Recruiting Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Conditions: Micropapillary Serous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen Citrate;   Drug: Topotecan Hydrochloride;   Drug: Trametinib
7 Recruiting A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Neoplasms;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Interventions: Drug: Trabectedin;   Drug: DOXIL;   Drug: Dexamethasone
8 Recruiting Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Chemotherapeutic Agent Toxicity;   Cognitive Side Effects of Cancer Therapy;   Psychological Impact of Cancer;   Radiation Toxicity;   Sexual Dysfunction and Infertility;   Stage IB Cervical Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer
Interventions: Drug: Carboplatin;   Drug: Cisplatin;   Radiation: External Beam Radiation Therapy;   Radiation: Internal Radiation Therapy;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
9 Recruiting Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Conditions: Breast Carcinoma;   Carcinoma of Unknown Primary Origin;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Carcinoma;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma
Interventions: Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
10 Recruiting Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Brenner Tumor;   Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Behavioral: Behavioral Dietary Intervention;   Behavioral: Compliance Monitoring;   Other: Counseling;   Other: Educational Intervention;   Behavioral: Exercise Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration

Study has passed its completion date and status has not been verified in more than two years.